Glenmark Pharma Selects I-many ContractSphere for Life Sciences

    Business Editors

    EDISON, N.J.--(BUSINESS WIRE)--April 20, 2005--

    Glenmark Pharmaceutical Inc. to Leverage I-many ContractSphere(R) for Life Sciences as the Foundation to Automate Rebates Processing and
    Streamline Medicaid Compliance

    I-many, Inc. (NASDAQ:IMNY), a provider of advanced Enterprise Contract Management (ECM) for managing corporate commitments, today announced that Glenmark Pharmaceuticals Inc. has chosen I-many CARS and Medicaid solutions to automate the management of chargeback and rebate processing as well as streamlining Medicaid compliance.
    Glenmark Pharmaceuticals Inc. is a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., a global, fully integrated, research-based pharmaceutical company headquartered in Mumbai, India. The company has generic formulation and API business interests in over 65 countries across the world. The formulation business spans several product segments such as Dermatology, Internal Medicine, Pediatrics, Gynecology, ENT and Diabetes. The company in also engaged in cutting-edge research in discovering new molecules and runs discovery projects in the areas of inflammation (Asthma/COPD, etc.) and metabolic disorders (Diabetes, Obesity, etc.). It has a compound in clinical trials for the indications of Asthma/COPD.
    "Glenmark's decision to invest in this system is in line with our plans to build a robust US commercial sales front-end in a short time, to market generic products," said Terrance Coughlin, president of Glenmark Pharmaceuticals Inc. "In a relatively short time Glenmark has commenced selling two in-licensed generics in the US, filed 6 ANDAs (March 2005), acquired two dossiers from Clonmel Healthcare and tied up with another Indian company to develop and market an additional 12 Generics. The company is also planning to file an additional 12-14 Generics by March 2006."
    "We selected I-many due to the extensive functionality in their products and their deep industry knowledge in life sciences," said Rick Sklar, chief financial officer of Glenmark Pharmaceuticals Inc. "I-many provides comprehensive and proven solutions to manage all of our requirements and has the best systems infrastructure available today to help us achieve our objectives."
    "Glenmark's selection of I-many CARS and Medicaid is a clear reflection of the need for life sciences companies to address critical rebate, chargeback and Medicaid processes with proven solutions that span commercial and governmental regulations and requirements," said Leigh Powell, president and CEO of I-many. "I-many's unsurpassed ability to combine superior software products with deep industry expertise helps companies like Glenmark mitigate the risk associated with implementing automated solutions to help achieve strategic and operational objectives. I-many is very pleased to welcome Glenmark as a new client and business partner for many years to come."

    About I-many

    I-many (NASDAQ:IMNY) delivers the most advanced Enterprise Contract Management solutions for managing corporate commitments. Designed to extend beyond the traditional contract management capabilities, I-many ContractSphere(R) offers an end-to-end solution, from pre-contract processes and contract management to transaction compliance. Ultimately, this provides companies with the visibility and control needed to manage any type of commitments - from contracts and obligations to payments and collections. The result is increased revenue, minimized risk and dramatically reduced operating costs, which deliver improved profitability with hard return on investment. More than 280 customers across 21 industries worldwide have implemented and realized the value of I-many business solutions. For more information, please visit www.imany.com.

    This news release contains forward-looking statements, and actual results may vary from those expressed or implied herein. Factors that could affect these results include: the risk of unforeseen technical or practical impediments to planned software development and other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission.

--30--ML/ny*

CONTACT: I-many, Inc. Dennis Wong, 650-226-1535 dwong@imany.com

KEYWORD: NEW JERSEY INDUSTRY KEYWORD: MEDICAL BANKING PHARMACEUTICAL SOFTWARE PRODUCT SOURCE: I-many, Inc.

Copyright Business Wire 2005